Skip Nav Destination
Drug Discovery
Drug Discovery for Schizophrenia
Edited by
Tatiana Lipina;
Tatiana Lipina
Institute of Physiology and Fundamental Medicine, Russia
Search for other works by this author on:
John Roder
John Roder
Lunenfeld-Tanenbaum Research Institute, Canada
Search for other works by this author on:
Hardback ISBN:
978-1-78262-026-6
PDF ISBN:
978-1-78262-249-9
EPUB ISBN:
978-1-78262-504-9
Special Collection:
2015 ebook collection
,
2011-2015 industrial and pharmaceutical chemistry subject collection
Series:
Drug Discovery
No. of Pages:
289
Publication date:
28 Apr 2015
About this book
Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. Drug Discovery for Schizophrenia covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery. The book outlines a change in the way schizophrenia is treated by moving away from focusing only on treating symptoms in patients. Innovative drugs emerge from deeper comprehension of the pathological processes that emerge earlier in life, hence, providing strategies for preventative therapy to alter the course of this mental disorder. Amongst other current topics, the book covers new findings in genetics and epigenetics, progress in animal models for schizophrenia and the usage of induced pluripotent stem cells. The combination of these important areas benefit psychiatric neuroscience, filling the gaps in the knowledge of neurobiology of schizophrenia and providing novel perspectives for future drug development.
Drug Discovery for Schizophrenia, The Royal Society of Chemistry, 2015.
Download citation file:
Digital access
$237.00
Print format
Drug Discovery for Schizophrenia
$237.00
Table of contents
-
CHAPTER 1: The Genetics of Schizophreniap1-27ByJames N. Samson;James N. SamsonCampbell Family Mental Health Research Institute, Centre for Addiction and Mental HealthTorontoOntarioCanadaSearch for other works by this author on:Albert H. C. WongAlbert H. C. WongCampbell Family Mental Health Research Institute, Centre for Addiction and Mental HealthTorontoOntarioCanadaSearch for other works by this author on:
-
CHAPTER 2: The Impact of Epigenetics in Schizophrenia Researchp28-45ByPeter J. Gebicke-HaerterPeter J. Gebicke-HaerterCentral Institute of Mental Health, Institute of Psychopharmacology, Medical Faculty Mannheim, University of HeidelbergJ568159 MannheimGermany[email protected]Programme of Molecular and Clinical Pharmacology, ICBM, Medical Faculty, University of ChileAv. Independencia 1027Santiago 7Chile[email protected]Search for other works by this author on:
-
CHAPTER 3: Developmental Neuroimmune Mechanisms in Schizophreniap46-69ByUlrike Stadlbauer;Ulrike StadlbauerPhysiology and Behaviour LaboratoryETH ZurichSchorenstrasse 168603 SchwerzenbachSwitzerland[email protected]Search for other works by this author on:Urs MeyerUrs MeyerPhysiology and Behaviour LaboratoryETH ZurichSchorenstrasse 168603 SchwerzenbachSwitzerland[email protected]Search for other works by this author on:
-
CHAPTER 4: The Self-medication Hypothesis in Schizophrenia: What Have We Learned from Animal Models?p70-88ByBernard Le Foll;Bernard Le FollTranslational Addiction Research Laboratory, Centre for Addiction and Mental Health33 Russell StreetTorontoOntario, M5S 2S1CanadaAmbulatory Care and Structured Treatment Program, Centre for Addiction and Mental Health33 Russell StreetTorontoOntario, M5S 2S1Canada[email protected]Departments of Family and Community Medicine, Pharmacology, Psychiatry, Institute of Medical Sciences, University of TorontoTorontoCanadaSearch for other works by this author on:Enoch Ng;Enoch NgLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital600 University AvenueTorontoOntario, M5G 1X5CanadaSearch for other works by this author on:José M. Trigo;José M. TrigoTranslational Addiction Research Laboratory, Centre for Addiction and Mental Health33 Russell StreetTorontoOntario, M5S 2S1CanadaSearch for other works by this author on:Patricia Di CianoPatricia Di CianoTranslational Addiction Research Laboratory, Centre for Addiction and Mental Health33 Russell StreetTorontoOntario, M5S 2S1CanadaSearch for other works by this author on:
-
CHAPTER 5: Modelling Schizophrenia: Strategies for Identifying Improved Platforms for Drug Discoveryp89-114ByJohn L. Waddington;John L. WaddingtonMolecular and Cellular Therapeutics, Royal College of Surgeons in IrelandDublinIrelandJiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psychiatric-Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow UniversitySuzhouChinaSearch for other works by this author on:Colm M. P. O’TuathaighColm M. P. O’TuathaighSchool of Medicine, University College Cork, Brookfield Health Sciences ComplexCorkIreland[email protected]Search for other works by this author on:
-
CHAPTER 6: Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophreniap115-140ByCatharine A. Mielnik;Catharine A. MielnikDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto1 King’s College CircleTorontoOntario, M5S 1A8Canada[email protected]Search for other works by this author on:Amy J. RamseyAmy J. RamseyDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto1 King’s College CircleTorontoOntario, M5S 1A8Canada[email protected]Search for other works by this author on:
-
CHAPTER 7: Disrupted-in-Schizophrenia-1 (DISC1) Interactome and Schizophreniap141-172ByTatiana V. Lipina;Tatiana V. LipinaLunenfeld Tanenbaum Research Institute at Mount Sinai HospitalTorontoOntario, M5G 1X5Canada[email protected]Search for other works by this author on:John C. RoderJohn C. RoderLunenfeld Tanenbaum Research Institute at Mount Sinai HospitalTorontoOntario, M5G 1X5Canada[email protected]Departments of Medical Biophysics and Molecular & Medical Genetics, University of TorontoTorontoOntarioCanadaSearch for other works by this author on:
-
CHAPTER 8: GSK3 Networks in Schizophreniap173-201ByJivan Khlghatyan;Jivan KhlghatyanDepartment of Psychiatry and Neuroscience, Faculty of Medicine, Laval University1050, Avenue de la MédecineQuébec CityQuébecCanadaInstitut Universitaire en Santé Mentale de Québec2601, Chemin de la CanardièreQuébec CityQuébecCanada[email protected]Search for other works by this author on:Gohar Fakhfouri;Gohar FakhfouriDepartment of Psychiatry and Neuroscience, Faculty of Medicine, Laval University1050, Avenue de la MédecineQuébec CityQuébecCanadaInstitut Universitaire en Santé Mentale de Québec2601, Chemin de la CanardièreQuébec CityQuébecCanada[email protected]Search for other works by this author on:Jean-Martin BeaulieuJean-Martin BeaulieuDepartment of Psychiatry and Neuroscience, Faculty of Medicine, Laval University1050, Avenue de la MédecineQuébec CityQuébecCanadaInstitut Universitaire en Santé Mentale de Québec2601, Chemin de la CanardièreQuébec CityQuébecCanada[email protected]Search for other works by this author on:
-
CHAPTER 9: Protein Interactions with Dopamine Receptors as Potential New Drug Targets for Treating Schizophreniap202-233ByPing Su;Ping SuDepartment of Neuroscience, Centre for Addiction and Mental HealthTorontoOntarioCanadaSearch for other works by this author on:Albert H. C. Wong;Albert H. C. WongDepartment of Neuroscience, Centre for Addiction and Mental HealthTorontoOntarioCanadaSearch for other works by this author on:Fang LiuFang LiuDepartment of Neuroscience, Centre for Addiction and Mental HealthTorontoOntarioCanadaSearch for other works by this author on:
-
CHAPTER 10: Optogenetic and Chemogenetic Tools for Drug Discovery in Schizophreniap234-272ByDennis Kätzel;Dennis KätzelInstitute of Neurology, University College LondonQueen Square, WC1N 3BGLondonUKDept of Experimental Psychology, University of Oxford9 South Parks Road, OX1 3UDOxfordUK[email protected]Search for other works by this author on:Dimitri M. KullmannDimitri M. KullmannInstitute of Neurology, University College LondonQueen Square, WC1N 3BGLondonUKSearch for other works by this author on:
Spotlight
Advertisement
Advertisement
